'I forgot what it's like to be outside': Intensive care ward opens on rooftop - BBC

Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD In written comments to Pharmacy Times, Parminder K. Judge, PhD, MBChB, MRCP, associate professor at Oxford Population Health and honorary consultant nephrologist at Oxford University Hospitals, discussed monitoring patients with chronic kidney disease (CKD) whose blood pressure (BP) treatment is intensified. Judge is the corresponding author of a JAMA Cardiology meta-analysis that Pharmacy Times previously reported found that intensive BP control cuts cardiovascular (CV) risk regardless of CKD status.1,2The meta-analysis of 27 trials found that intensive BP lowering did not increase kidney failure but did increase sustained declines in estimated glomerular filtration rate (eGFR), which the authors suggested may reflect hemodynamic responses to added diuretic therapy.1,2Building on those findings, Judge said decisions to target a systolic BP below 120 mm Hg should be personalized, as that target would not be appropriate for all patients with CKD.

IntroductionHow does the gut microbiome change as we age? The link between gut microbiome changes and inflammationGut microbiome and age-related health conditionsCan the gut microbiome be targeted to promote longevity? From microbial shifts in later life to the distinctive gut communities of centenarians, researchers are investigating what the intestinal microbes reveal about how people age.

IntroductionClinical trial evidenceFDA approval and regulatory developmentsCardiometabolic and secondary benefitsFuture directionsReferences What can treatments targeting weight and metabolism offer people with obstructive sleep apnea, and which questions must clinical trials still answer?

A common liver disease affecting nearly 30% of adults worldwide is far more complex than previously understood. Researchers at Mayo Clinic have identified five biologically distinct forms of the condition, each associated with different risks of serious health complications, including heart disease, liver failure, cancer, and the need for a liver transplant. The findings, published in Nature Communications, come from a collaboration between Mayo Clinic and Virginia Tech. Scientists discovered that metabolic dysfunction-associated steatotic liver disease, or MASLD, can develop through several different biological pathways. Some are closely connected to obesity and diabetes, while others appear to be driven by inherited genetic differences.